文献速递角膜与眼表疾病神经眼科

伐昔洛韦预防带状疱疹眼病的时变效应:ZEDS试验事后探索性分析

Time-Varying Effects of Valacyclovir Prophylaxis in the Zoster Eye Disease Study: A Post Hoc Exploratory Analysis of a Randomized Clinical Trial.
PubMed 文献 · JAMA Ophthalmol · 2026-01-01

该研究为ZEDS随机临床试验的事后探索性分析,纳入527例带状疱疹眼病患者,评估12个月伐昔洛韦抑制治疗对减少角膜炎或虹膜炎复发的时变效应。

要点

  • 保护效应局限于早期治疗和观察期,支持先前发表的1年预防性用药推荐。

核心结论

  • 在本ZEDS随机临床试验的事后探索性分析中,预防性伐昔洛韦降低带状疱疹相关角膜炎和虹膜炎的后续发生概率,但未达到统计学显著性。
  • 伐昔洛韦预防的保护效应局限于早期治疗期和观察期,支持先前发表的1年预防性用药推荐。

研究设计与样本

  • 共651例参与者知情同意,527例随机分组(按发病年龄和慢性程度分层),490例完成12个月随访,460例完成18个月随访。
  • 纳入标准为免疫正常、非妊娠成人,有带状疱疹眼病皮疹史,1年内有活动性角膜炎或虹膜炎记录,估算肾小球滤过率≥45 mL/min/1.73 m²。
  • 干预为12个月双盲每日伐昔洛韦1000 mg或安慰剂,随后6个月观察性随访。
  • 主要结局为从随机分组到首次发生新发或加重的基质角膜炎、内皮角膜炎、虹膜炎或树枝状上皮角膜炎的时间。

主要发现

  • 参与者中位年龄60岁(IQR 50-68),527例中266例(50.5%)为女性。
  • Cox比例风险分析和限制性平均生存时间分析提示伐昔洛韦在早期治疗期和观察期较安慰剂获益更大。

关键数值与推荐

  • 主要结局定义为随机分组至首次发生新发或加重的基质角膜炎、内皮角膜炎、虹膜炎或树枝状上皮角膜炎的时间。

临床怎么用

  • 对于有带状疱疹眼病病史且1年内有活动性角膜炎或虹膜炎的免疫正常成人,可考虑1年预防性伐昔洛韦治疗以降低复发风险。
  • 保护效应在治疗早期和观察期更明显,提示预防性用药的获益可能随时间变化。

局限性

  • 该研究为事后探索性分析,主要结局未显示统计学显著性,结果需谨慎解读。
  • 原文未报告其他局限性信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The Zoster Eye Disease Study (ZEDS) supports consideration of suppressive valacyclovir for 1 year to reduce risk of recurrent keratitis or iritis in patients with herpes zoster ophthalmicus (HZO). Although the primary outcome did not show benefit of suppressive valacyclovir treatment, secondary study outcomes showed treatment superiority at the 18-month end point and reduced number of multiple episodes of keratitis or iritis at both 12 and 18 months; however, it is unknown if these possible protective effects vary over time. OBJECTIVE: To assess for temporal patterns of potential benefit of suppressive valacyclovir treatment to reduce risk of new or worsening stromal keratitis (SK), endothelial keratitis (EK), iritis (IR), or dendriform epithelial keratitis (DEK). DESIGN, SETTING, AND PARTICIPANTS: This is a post hoc exploratory analysis of a multicenter, double-masked, placebo-controlled randomized clinical trial conducted in 95 centers from November 2017 to January 2023. Immunocompetent, nonpregnant adults with history of HZO rash, documented active keratitis or IR within 1 year, and estimated glomerular filtration rate of 45 mL/min/1.73 m2 or greater were eligible. Data were analyzed from September 2025 through December 2025. INTERVENTION: Twelve months of double-masked daily valacyclovir, 1000 mg, or placebo, with 6 months of observational follow-up. MAIN OUTCOMES AND MEASURES: The primary outcome was the time from randomization to first occurrence of new or worsening SK, EK, IR, or DEK. RESULTS: A total of 651 participants consented and 527 were randomized (stratified by age at onset and chronicity), while 490 participants completed 12 months and 460 completed 18 months. Median (IQR) participant age was 60 years (50-68), and 266 of 527 patients (50.5%) were female. Cox proportional hazards and restricted mean survival time analyses of ZEDS data suggested greater benefit of valacyclovir over placebo in early treatment and observational periods. Time-varying Cox analyses showed lower hazards for valacyclovir during the treatment interval (hazard ratio [HR], 0.77; 95% CI, 0.56-1.05; P = .09) for 0 to 12 months and the observation interval (HR, 0.57; 95% CI, 0.27-1.18; P = .12) for more than 12 to 18 months, with lower hazard from 0 to 6 months (HR, 0.71; 95% CI, 0.49-1.01; P = .06) than from more than 6 to 12 months (HR, 0.99; 95% CI, 0.52-1.86; P = .97). CONCLUSIONS AND RELEVANCE: In this post hoc exploratory analysis of the ZEDS randomized clinical trial, prophylactic valacyclovir decreased probability of subsequent zoster-related keratitis and IR, although statistical significance was not reached. Protective effects of valacyclovir prophylaxis were localized to early treatment and observation periods, supporting previously published recommendation of 1 year of prophylaxis. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03134196.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Warner DB, Lee TF, Troxel AB, et al. Time-Varying Effects of Valacyclovir Prophylaxis in the Zoster Eye Disease Study: A Post Hoc Exploratory Analysis of a Randomized Clinical Trial. JAMA Ophthalmol. 2026. PMID: 42593809. doi:10.1001/jamaophthalmol.2026.3202

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。